Tag : MRI

CONFERENCE UPDATE

Tolebrutinib slows disability progression in nrSPMS: Results from the phase 3 HERCULES trial
The phase 3 HERCULES trial demonstrates that tolebrutinib reduces disability progression in non-relapsing secondary progressive multiple sclerosis (nrSPMS) by 31%, offering hope for this underserved population.
CONFERENCE UPDATE

Novel MRI-based H-SeLECT risk score enhances the prediction of post-stroke epilepsy
Stroke is one of the most common causes of adult-onset seizures, which may occur early (≤7 days) or late (>7 days) after stroke. Post-stroke epilepsy (PSE) is defined as any unprovoked seizure after the acute phase (>7 days) of stroke.